US Pharma MarketingPraxis sinks on late-stage study fail for seizure pill, halts second trial
On Monday, Praxis disclosed a late-stage failure for its investigational seizure medicine, and the company is pausing enrollment in a second trial while it figures out what to do. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure…
Praxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins.
But on Monday, the company disclosed a late-stage failure for its investigational seizure medicine, and ...
Source: Endpoints News